Maze Therapeutics announces license agreement with Sanofi for MZE001
The Fly

Maze Therapeutics announces license agreement with Sanofi for MZE001

Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications. MZE001, designed and developed by Maze, is an oral GYS1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation. Under the terms of the agreement, Maze will receive a $150M payment consisting of both upfront cash and future equity investment for the rights to further develop and commercialize MZE001, as well as an exclusive license to related GYS1-targeting back-up programs and intellectual property. Maze will be eligible to receive up to an additional approximately $600M in potential development, regulatory and sales milestones, as well as meaningful royalties on sales if MZE001 is successfully commercialized.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SNY:

Related Articles
TheFlySanofi price target raised to EUR 130 from EUR 125 at Citi
TheFlySanofi shipping BEYFORTUS 50mg, 100mg injection doses in U.S.
TipRanks Auto-Generated NewsdeskSanofi’s Dupixent Shows Promise for Skin Disease
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App